Modis Therapeutics Announces Presentation at International World Muscle Society Congress 2018

Presentation by Dr. Michio Hirano on Mitochondrial DNA Depletion Disorders will Highlight Clinical Data on Treatment of Thymidine Kinase 2 Deficiency (TK2d) with Deoxynucleoside Therapy

OAKLAND, Calif., Oct. 3, 2018 /PRNewswire/ -- Modis Therapeutics announced today that Dr. Michio Hirano, Professor of Neurology and Chief of the Division of Neuromuscular Medicine, Columbia University Irving Medical Center, has been invited to speak at the 23^rd International Annual Congress of the World Muscle Society (WMS) which is being held October 2-6 in Mendoza, Argentina.

The invited lecture, "Deoxynucleoside Therapy for Mitochondrial DNA Depletion Disorders," will be held during the Mitochondrial Disease II session from 11am to 12pm ART on October 4^th.  The presentation will highlight clinical results of treatment of TK2d patients with deoxynucleoside therapy.  Modis Therapeutics is working with Dr. Hirano, Columbia University Irving Medical Center and a consortium of international collaborators to develop deoxynucleoside combination therapy, MT1621, for TK2d.  The data presented is part of a larger cohort being analyzed in a Modis sponsored study.

Dr. Carmen Paradas, Neurologist and Clinical Researcher in the Neuromuscular Diseases Unit at Hospital Universitario Virgen del Rocio and Instituto de Biomedicina de Sevilla, commented, "My colleagues and I have treated a number of TK2 patients and have found that deoxynucleosides provide clear clinical benefit in infantile, childhood and adult-onset patients as compared to the morbidity and mortality reported in two recently published natural history studies of TK2d." ^1,2

About Modis Therapeutics
Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need. It was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company's lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland, CA, with offices in New York City.  For more information please visit www.modistx.com.

About TK2 Deficiency
Thymidine kinase 2 deficiency (TK2d) is a genetic disorder that results in mitochondrial dysfunction, leading to inadequate energy production in cells. TK2d may present at all ages and causes progressive and severe muscle weakness, respiratory insufficiency, and is often fatal. There are currently no approved therapies for this disease. To learn more, please visit www.tk2d.com.

Contact:
Aaron Mishel
VP Finance & Administration
Modis Therapeutics, Inc.
(510) 806-8564
amishel@modistx.com

References:

1. Wang, Julia; Kim, Emily; Dai, Honzheng; Stefans, Vikki; Vogel, Hannes; Al Jasmi, Fatma et al. (2018): Clinical and molecular spectrum of thymidine kinase 2-related mtDNA maintenance defect. In Molecular genetics and metabolism 124 (2), pp. 124–130. DOI: 10.1016/j.ymgme.2018.04.012.
2. Garone, Caterina; Taylor, Robert W.; Nascimento, Andrés; Poulton, Joanna; Fratter, Carl; Domínguez-González, Cristina et al. (2018): Retrospective natural history of thymidine kinase 2 deficiency. In Journal of medical genetics. DOI: 10.1136/jmedgenet-2017-105012.

View original content to download multimedia:http://www.prnewswire.com/news-releases/modis-therapeutics-announces-presentation-at-international-world-muscle-society-congress-2018-300723319.html

SOURCE Modis Therapeutics, Inc.